Fair Pharmacies for Federal Employees Act of 2025
- Bill Number
- H.R. 4409
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-07-15: Referred to the House Committee on Oversight and Government Reform.
- Last Updated
- 2025-09-11T15:58:42Z
AI-Generated Summary
Purpose
The Fair Pharmacies for Federal Employees Act of 2025 aims to promote fair competition in the pharmacy services provided through federal employee health plans by prohibiting shared ownership or control between pharmacies and pharmacy benefit managers (PBMs). PBMs are companies that manage prescription drug benefits for health plans, negotiating prices and creating pharmacy networks. This legislation seeks to prevent potential conflicts of interest or anticompetitive practices in these plans, which cover health benefits for federal workers.
Key Provisions
- Prohibitions on Ownership and Contracts:
- The Office of Personnel Management (OPM), which oversees federal employee health benefits, cannot enter contracts with health insurance carriers (qualified carriers) that own, operate, or control any pharmacy.
- OPM or these carriers cannot contract or subcontract with PBMs that own, operate, or control any pharmacy.
- These rules apply to direct or indirect ownership, including through affiliates or subsidiaries.
- Rule of Construction: The law does not restrict the powers of agencies like the Federal Trade Commission (FTC), the Department of Justice's Inspector General, the Department of Health and Human Services (HHS), or state attorneys general to enforce other antitrust or related laws.
- Definitions:
- Pharmacy: Broadly defined to include any licensed entity dispensing prescription drugs or controlled substances, such as retail, mail-order, hospital, or specialty pharmacies.
- Pharmacy Benefit Manager (PBM): An entity that negotiates drug prices, manages pharmacy networks, processes claims, or handles other prescription drug benefits for health plans.
- Qualified Carrier: Nongovernmental organizations providing health insurance or benefits under group plans.
- Other terms like "health plan" and "person" align with standard legal definitions from antitrust laws.
Significant Changes to Existing Law
This bill introduces new restrictions specifically for federal employee health plans, which were not previously prohibited under current federal law. It builds on existing antitrust frameworks (e.g., the Sherman Act) but targets vertical integration—where the same company or affiliates control both drug pricing negotiations (via PBMs) and dispensing (via pharmacies)—in government-contracted plans. Prior to this, such ownership was allowed as long as it complied with general competition rules.
Potential Impacts
- On Government Agencies: OPM will need to review and modify its contracting processes to ensure compliance, potentially increasing administrative oversight and audits of carriers and PBMs. Other agencies like the FTC and HHS may see indirect benefits through preserved enforcement authority.
- On Citizens: Federal employees and retirees (over 8 million beneficiaries) could experience more competitive pharmacy options, possibly leading to lower drug costs, broader access to independent pharmacies, and reduced influence of large integrated firms on pricing and networks.
- On International Relations: No direct impacts, as the bill focuses on domestic federal health plans and U.S.-based entities.
Main Stakeholders Affected
- Federal Employees and Retirees: Primary beneficiaries who rely on these health plans for prescription drug coverage.
- Office of Personnel Management (OPM): Responsible for implementing and enforcing the prohibitions in contracts.
- Qualified Carriers and PBMs: Insurance providers and drug benefit managers (e.g., large firms like CVS Caremark or Express Scripts) that may need to restructure ownership or partnerships to maintain federal contracts.
- Pharmacies: Independent and chain pharmacies, which could gain more opportunities to participate in federal networks without competition from vertically integrated entities.
- Regulatory Agencies: FTC, HHS, and state attorneys general, who retain tools to address broader anticompetitive issues.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens antitrust protections in a specific sector by codifying ownership bans, potentially serving as a model for similar restrictions in other health programs like Medicare. It avoids limiting existing enforcement tools, ensuring compatibility with laws like the Sherman Act (which prohibits monopolies and restraints of trade).
- Constitutional: No apparent challenges; the bill regulates federal spending and contracts, falling under Congress's commerce and spending powers.
- Political: Introduced bipartisanship (Democrat and Republican sponsors) reflects growing concerns over PBM practices and drug pricing. If enacted, it could influence broader debates on healthcare competition without mandating changes to private-sector arrangements.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Krishnamoorthi, Raja [D-IL-8]
Cosponsors (2)
Rep. Harshbarger, Diana [R-TN-1], Rep. Schneider, Bradley Scott [D-IL-10]
Recent Actions
- 2025-07-15: Referred to the House Committee on Oversight and Government Reform.
- 2025-07-15: Introduced in House
- 2025-07-15: Introduced in House
Bill Versions
- Fair Pharmacies for Federal Employees Act of 2025 — issued 2025-07-15 — PDF (6 pages)